DiaSorin Molecular, Cypress, Calif, has released a new primer pair that targets the yeast Candida auris, for use in creating laboratory-developed molecular tests. The new product joins the company’s menu of more than 65 primer pairs for bacterial, fungal, and viral targets as well as human genetic mutations. The primer pairs are classified as analyte-specific reagents (ASRs), and can be used by high-complexity laboratories to create their own laboratory-developed tests.
Michelle Tabb, PhD, DiaSorin Molecular.
C. auris is an emerging drug-resistant yeast that spreads in healthcare facilities and is a serious global health threat. It is often difficult to identify using nonmolecular methods, with misidentification leading to poor and costly patient management. The yeast has caused recent outbreaks in hospitals and long-term care facilities across the United States and in more than 20 countries. Since the organism is becoming more common, timely identification is required for effective mitigation of the threat.
“We are proud to offer the first commercially available molecular ASR targeting Candida auris,” says Michelle Tabb, PhD, chief scientific officer at DiaSorin Molecular. “DiaSorin strives to listen and respond to customers regarding their needs for molecular infectious disease products.”
For more information, visit DiaSorin Molecular.
Interested in your diagnostics tests for Candida sp.